One To Watch

SK biopharmaceuticals

A South Korean biotech advancing a neurology-focused pipeline anchored by its commercially approved antiseizure medication cenobamate, while expanding into radiopharmaceuticals and ophthalmology.

Company Overview

A South Korean biotech advancing a neurology-focused pipeline anchored by its commercially approved antiseizure medication cenobamate, while expanding into radiopharmaceuticals and ophthalmology. SK Biopharmaceuticals operates through its U.S. commercialization arm SK Life Science, Inc. and research entity SK Life Science Labs. The company sits within the broader SK Group conglomerate and is pursuing a strategy to become a global biotech leader by leveraging group synergies and external partnerships.

Headquarters and Global Presence

SK Biopharmaceuticals is headquartered in Seoul, South Korea. It maintains a significant U.S. operational presence through SK Life Science, Inc. and SK Life Science Labs, which handle commercial and R&D activities for the North American market respectively.

Founding and History

SK Biopharmaceuticals was established as the pharmaceutical research and development division of SK Group, one of South Korea's largest conglomerates. The company's defining milestone came with the independent development and U.S. approval of cenobamate (XCOPRI), marking it as one of the few Korean biotechs to bring a novel CNS compound through to U.S. commercial launch. The company is listed on the Korea Exchange and has progressively expanded its pipeline and geographic reach since commercialization.

Therapy Areas and Focus

Neurology forms the core of SK Biopharmaceuticals' therapeutic focus, with epilepsy as its primary indication and an emerging interest in other CNS conditions. The company is also moving into ophthalmology through its glaucoma collaboration and is building early-stage capabilities in radiopharmaceutical oncology. This diversification reflects a deliberate strategy to grow beyond its CNS heritage while maintaining leadership in antiseizure drug development.

Technology Platforms and Modalities

SK Biopharmaceuticals works primarily in small molecule drug discovery, with cenobamate representing the flagship output of its CNS chemistry platform. The compound's proposed dual mechanism — enhancing inhibitory GABA-A currents and reducing persistent sodium currents — underpins its clinical differentiation in focal-onset seizures. In radiopharmaceuticals, the company is pursuing actinium-225-based targeted therapies through a collaborative research agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS), signed in November 2024, as a foundation for oncology expansion.

Key Pipeline and Programs

Cenobamate (XCOPRI) is SK Biopharmaceuticals' approved and commercialized antiseizure medication, a small molecule with a proposed dual mechanism targeting GABA-A receptors and persistent sodium currents. It is approved in the United States for focal-onset seizures in adults and has been out-licensed to Eurofarma for Latin America. Phase III data in Northeast Asian epilepsy patients were presented at the 2024 American Epilepsy Society Annual Meeting in December 2024, supporting potential label expansions and regional approvals.

Azetukalner is a pipeline asset that showed Phase III promise in difficult-to-treat epilepsy patients, with data emerging in April 2026 highlighting its potential in refractory populations. The compound adds to the company's ambition to maintain a leading position across the antiseizure drug landscape.

SKL-G is a novel small molecule in development for glaucoma, representing SK Biopharmaceuticals' entry into ophthalmology. A collaboration agreement with Korean biotech AriBio was signed in June 2024 to jointly advance SKL-G, with the partnership combining SK's chemistry platform with AriBio's disease expertise.

Recent Developments

In July 2025, SK Biopharmaceuticals announced a joint venture with Eurofarma to develop an AI-driven digital health initiative in the U.S., deepening a relationship established in 2022 through the Latin America out-licensing of cenobamate. Phase III data for cenobamate in Northeast Asian patients were presented at the AES Annual Meeting in December 2024, strengthening the regional regulatory case. In November 2024, the company signed its first actinium-225-based collaborative research agreement with KIRAMS, marking a formal step toward radiopharmaceutical oncology. Azetukalner demonstrated Phase III promise in difficult epilepsy patients in April 2026.

Key Personnel

Donghoon Lee serves as Chief Executive Officer and President of SK Biopharmaceuticals and its U.S. subsidiaries SK Life Science, Inc. and SK Life Science Labs. His strategic mandate is to transform the group into a global biotech leader while generating synergy across SK Group affiliates and external partners.

Strategic Partnerships

SK Biopharmaceuticals out-licensed cenobamate to Brazil-based Eurofarma in 2022 for development and commercialization across Latin America, and in 2025 the two companies announced a joint venture focused on AI-based digital health in the U.S. market. In June 2024, the company entered a collaboration with AriBio to co-develop SKL-G for glaucoma. A research agreement with KIRAMS, signed November 2024, anchors the company's radiopharmaceutical oncology ambitions.

FAQ Section

The company is pursuing a three-pronged expansion beyond cenobamate: advancing azetukalner in refractory epilepsy populations, entering ophthalmology through the SKL-G glaucoma collaboration with AriBio, and building a radiopharmaceutical oncology platform via its actinium-225 research agreement with KIRAMS signed in late 2024. The Eurofarma joint venture on AI digital health further signals ambitions to move into digital therapeutics adjacent to its core CNS commercialization. Together these initiatives reflect a deliberate pivot from single-product dependence toward a diversified biotech portfolio.

Cenobamate is proposed to work through a dual mechanism: enhancing the inhibitory activity of GABA-A ion channels while also reducing persistent sodium currents that sustain repetitive neuronal firing. This dual action distinguishes it from most antiseizure drugs that target only one pathway, and is thought to contribute to its efficacy in patients who have failed prior treatments. The compound received U.S. FDA approval for focal-onset seizures in adults, and Phase III data in Northeast Asian patients presented at the 2024 AES Annual Meeting suggest its profile translates across ethnic populations.

SK Biopharmaceuticals is unusual among Korean biotechs in having independently discovered, developed, and commercially launched an innovative CNS drug in the United States — a feat few companies from South Korea have accomplished. Its U.S. subsidiary SK Life Science, Inc. manages domestic commercialization directly rather than relying solely on third-party partners. This vertically integrated commercial infrastructure, combined with pipeline assets at multiple stages and a growing international licensing network, gives it a materially different operational profile from earlier-stage Korean CNS peers.

Azetukalner demonstrated Phase III promise in difficult-to-treat epilepsy patients, with data reported in April 2026, positioning it as a potential successor asset to cenobamate within SK's epilepsy franchise. Success in refractory populations — patients who have not responded to multiple prior medications — would address a high unmet clinical need and extend the company's competitive relevance beyond its approved drug. The compound's Phase III results are a key near-term inflection point for the company's neurology pipeline.

Neurology, specifically epilepsy, remains the dominant therapy area with both a commercialized product (cenobamate) and a clinical-stage asset (azetukalner). Ophthalmology is an emerging area through SKL-G for glaucoma, pursued in collaboration with AriBio since June 2024. Oncology via actinium-225 radiopharmaceuticals represents the earliest-stage diversification, underscored by the KIRAMS partnership, as the company seeks to build a future revenue pillar outside CNS.

SK Biopharmaceuticals is a commercial-stage company with cenobamate already approved and generating revenue in the United States and being rolled out in Latin America through Eurofarma. Azetukalner is at Phase III, making it the most advanced pipeline asset. SKL-G is in early collaborative development for glaucoma, while the actinium-225 radiopharmaceutical program is at the preclinical and research collaboration stage. The company thus spans the full development continuum, from research-stage oncology to a marketed CNS drug.

Key watchpoints include:

Azetukalner Phase III data interpretation and any regulatory submission timelines following the April 2026 readout.
Cenobamate Northeast Asian regulatory progress, supported by Phase III data presented at the 2024 AES Annual Meeting.
SKL-G collaboration milestones with AriBio and early clinical entry in glaucoma.
Progress and deal terms emerging from the Eurofarma AI digital health joint venture announced in 2025.
Execution risk on the radiopharmaceutical platform, which remains at an early research stage via KIRAMS.

Want to Update your Company's Profile?